Journal
DERMATOLOGIC THERAPY
Volume 26, Issue 5, Pages 400-403Publisher
WILEY
DOI: 10.1111/dth.12087
Keywords
bexarotene; cutaneous T cell lymphoma; retinoids
Categories
Ask authors/readers for more resources
Bexarotene is a retinoid that specifically binds retinoid X receptors and has numerous effects on cellular growth and differentiation. It is approved for the treatment of cutaneous T cell lymphoma both topically and systemically. Adverse effects include hyperlipidemia, central hypothyroidism, and neutropenia with bexarotene capsules, and an irritant dermatitis with bexarotene gel. With aggressive management of these potential side effects, bexarotene is an additional option in the armamentarium for management of cutaneous T cell lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available